mTORgátlók

mTORgátlók, also known as mTOR inhibitors, are a class of drugs that target the mechanistic target of rapamycin (mTOR) pathway. This pathway plays a crucial role in cell growth, proliferation, metabolism, and survival. By inhibiting mTOR, these drugs can slow down or stop the growth of cells, particularly rapidly dividing cells like cancer cells.

The primary applications of mTOR inhibitors are in cancer treatment and in preventing organ transplant rejection. In oncology, they are used to treat various types of cancer, including kidney cancer, breast cancer, and certain types of lymphoma. They work by disrupting the signaling cascades that promote tumor growth and angiogenesis (the formation of new blood vessels that supply tumors).

In organ transplantation, mTOR inhibitors are employed to suppress the immune system and prevent the body from rejecting the transplanted organ. They achieve this by interfering with the proliferation of T-cells, a key component of the immune response.

Common side effects of mTOR inhibitors can include mouth sores, fatigue, skin rash, diarrhea, and increased susceptibility to infections. The specific side effects and their severity can vary depending on the particular drug and the dosage used. Research into mTOR inhibitors is ongoing, with efforts focused on identifying new therapeutic targets and developing more effective and less toxic inhibitors.